Oncology NEWS International: February 2009 Volume 18 Number 2 Supplement 1
Supported by an unrestricted educational grant from AstraZeneca In this supplement to Oncology NEWS International, guest editor Aman U. Buzdar, MD, highlights key data presented at the December 2008 San Antonio Breast Cancer Symposium. In his in-depth commentary, Dr. Buzdar contextualizes these practice-changing study results and explains how the evolution of endocrine therapies has helped to change the natural history of early breast cancer and to prolong survival in metastatic disease.
Hot Topics in Breast Cancer: Optimizing the Use of Aromatase Inhibitors, Highlights from the 2008 San Antonio Breast Cancer Symposium
Supported by an unrestricted educational grant from AstraZeneca
In this supplement to Oncology NEWS International, guest editor Aman U. Buzdar, MD, highlights key data presented at the December 2008 San Antonio Breast Cancer Symposium. In his in-depth commentary, Dr. Buzdar contextualizes these practice-changing study results and explains how the evolution of endocrine therapies has helped to change the natural history of early breast cancer and to prolong survival in metastatic disease.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
